Group 1 - The company announced that its wholly-owned subsidiary EuroEyes Netherlands plans to acquire all issued share capital of FYEO Europe B.V. for a maximum consideration of approximately €145.8 million (around HK$1.234 billion) [1] - The acquisition is expected to be completed by July 15, 2026, assuming a zero loss amount [1] - The target company is a leading private refractive surgery platform in the Netherlands, specializing in laser treatments and lens implants [1] Group 2 - The board believes that the acquisition aligns with the company's strategic goals due to the high compatibility between the company and the target group, both being pure refractive surgery participants [2] - The target group is well-positioned for continued growth in the rapidly expanding Dutch market, supported by favorable growth levers such as increasing direct market access and advancements in refractive surgery technology [2] - The acquisition is expected to enhance the company's market position, improve overall competitiveness, ensure long-term sustainability, and create value for the company and its shareholders [2]
德视佳拟斥巨资收购荷兰屈光手术领军企业FYEO Europe B.V. 2月27日复牌